NASDAQ:TRAW Traws Pharma Q1 2025 Earnings Report $0.66 -0.03 (-4.73%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Traws Pharma EPS ResultsActual EPS$2.09Consensus EPS -$8.04Beat/MissBeat by +$10.13One Year Ago EPSN/ATraws Pharma Revenue ResultsActual Revenue$0.06 millionExpected Revenue$0.06 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/ATraws Pharma Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time7:00AM ETUpcoming EarningsTraws Pharma's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Traws Pharma Earnings HeadlinesTraws Pharma Stock Dividends | NASDAQ:TRAW | BenzingaJuly 8 at 3:45 AM | benzinga.comTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJune 22, 2026 | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 8 at 1:00 AM | Reagan Gold Group (Ad)Outlook for Bucks County biotech take another hit with second setback for flu drugJune 15, 2026 | bizjournals.comMicron, Nebius surge premarket; Traws Pharma tumblesJune 15, 2026 | finance.yahoo.comTraws Pharma shares slide after UK regulator postpones influenza studyJune 15, 2026 | msn.comSee More Traws Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email. Email Address About Traws PharmaTraws Pharma (NASDAQ:TRAW), a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.View Traws Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Exxon Could Be the Market's Next Big Comeback StockWhy Penguin Solutions May Be the Smartest AI Infrastructure StockMeta Platforms’ Cloud Push: Growth Opportunity Versus AI ConcernsThese 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialDrone Stocks Are Down, But Defense Backlogs Tell a Different StoryGE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
